Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Income Statement
Earnings Waterfall
Amylyx Pharmaceuticals Inc
Income Statement
Amylyx Pharmaceuticals Inc
| Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Revenue |
1
N/A
|
0
-55%
|
0
N/A
|
0
N/A
|
0
+21%
|
22
+6 343%
|
94
+321%
|
192
+105%
|
294
+53%
|
381
+29%
|
398
+5%
|
299
-25%
|
196
-34%
|
87
-56%
|
(1)
N/A
|
0
N/A
|
0
N/A
|
|
| Gross Profit | ||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
(0)
|
(3)
|
(8)
|
(14)
|
(19)
|
(25)
|
(44)
|
(46)
|
(41)
|
(32)
|
(8)
|
(1)
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
19
+11 020%
|
85
+344%
|
178
+108%
|
275
+55%
|
355
+29%
|
354
0%
|
253
-29%
|
155
-39%
|
55
-64%
|
(9)
N/A
|
(0)
+96%
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(64)
|
(83)
|
(118)
|
(154)
|
(185)
|
(221)
|
(241)
|
(259)
|
(283)
|
(317)
|
(343)
|
(315)
|
(276)
|
(218)
|
(222)
|
(160)
|
(157)
|
|
| Selling, General & Administrative |
(28)
|
(39)
|
(59)
|
(82)
|
(101)
|
(127)
|
(145)
|
(158)
|
(177)
|
(188)
|
(202)
|
(180)
|
(149)
|
(114)
|
(72)
|
(66)
|
(65)
|
|
| Research & Development |
(36)
|
(44)
|
(59)
|
(72)
|
(84)
|
(93)
|
(96)
|
(101)
|
(106)
|
(128)
|
(141)
|
(135)
|
(126)
|
(104)
|
(90)
|
(93)
|
(92)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(60)
|
0
|
0
|
|
| Operating Income |
(63)
N/A
|
(83)
-31%
|
(118)
-42%
|
(153)
-30%
|
(185)
-21%
|
(201)
-9%
|
(156)
+23%
|
(81)
+48%
|
(8)
+90%
|
39
N/A
|
11
-71%
|
(62)
N/A
|
(121)
-93%
|
(163)
-35%
|
(230)
-41%
|
(161)
+30%
|
(157)
+2%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
1
|
1
|
4
|
8
|
11
|
15
|
16
|
17
|
17
|
16
|
14
|
12
|
10
|
8
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(93)
|
(115)
|
(152)
|
(152)
|
0
|
(36)
|
0
|
|
| Total Other Income |
(5)
|
(5)
|
(4)
|
(0)
|
0
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Pre-Tax Income |
(68)
N/A
|
(88)
-29%
|
(121)
-38%
|
(153)
-26%
|
(184)
-20%
|
(198)
-7%
|
(148)
+25%
|
(71)
+52%
|
6
N/A
|
54
+853%
|
(66)
N/A
|
(162)
-147%
|
(257)
-59%
|
(302)
-17%
|
(219)
+27%
|
(188)
+14%
|
(150)
+20%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(2)
|
(4)
|
(5)
|
(5)
|
(4)
|
0
|
0
|
1
|
1
|
1
|
|
| Income from Continuing Operations |
(68)
|
(88)
|
(121)
|
(153)
|
(184)
|
(198)
|
(149)
|
(73)
|
2
|
49
|
(71)
|
(166)
|
(259)
|
(302)
|
(219)
|
(188)
|
(149)
|
|
| Net Income (Common) |
(68)
N/A
|
(88)
-29%
|
(121)
-38%
|
(153)
-27%
|
(184)
-20%
|
(198)
-8%
|
(149)
+25%
|
(73)
+51%
|
2
N/A
|
49
+2 584%
|
(71)
N/A
|
(166)
-133%
|
(259)
-56%
|
(302)
-16%
|
(219)
+27%
|
(188)
+14%
|
(149)
+20%
|
|
| EPS (Diluted) |
-1.21
N/A
|
-1.56
-29%
|
-2.34
-50%
|
-2.63
-12%
|
-3.14
-19%
|
-3.39
-8%
|
-2.1
+38%
|
-1.03
+51%
|
0.02
N/A
|
0.7
+3 400%
|
-1.04
N/A
|
-2.45
-136%
|
-3.82
-56%
|
-4.43
-16%
|
-2.55
+42%
|
-2.1
+18%
|
-1.59
+24%
|
|